+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Human Factor VIII Concentrate Market - Global Forecast 2026-2032- Product Image
Human Factor VIII Concentrate Market - Global Forecast 2026-2032- Product Image
Sale

Human Factor VIII Concentrate Market - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6144069
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Factor VIII Concentrate Market is projected to reach USD 3.79 Billion in 2026. It is expected to continue growing at a CAGR of 7.02%, reaching USD 5.68 Billion by 2032.

Human Factor VIII Concentrate: Executive Overview

Human factor VIII concentrate is a plasma-derived or recombinant replacement therapy used to prevent and control bleeding in people with hemophilia A and other clinically indicated factor VIII deficiencies. Its role is shaped by treatment safety, inhibitor management, product purity, supply continuity, administration requirements, and access to specialist hematology services. Care is increasingly organized around individualized prophylaxis, rapid treatment of breakthrough bleeding, home administration, and monitoring of adherence and outcomes.

Treatment Is Shifting Toward Personalized, Continuous Care

The treatment landscape is moving from episodic replacement toward individualized prophylaxis that considers bleeding history, activity level, pharmacokinetics, age, joint health, and treatment preferences. Longer-acting formulations, improved reconstitution and delivery systems, and digital adherence support can reduce treatment burden, although clinical suitability and availability differ across health systems. Inhibitor screening, immune tolerance strategies, surgical planning, and coordinated multidisciplinary care remain essential to safe use.

Artificial Intelligence Strengthens Dosing, Safety, and Supply Planning

Artificial intelligence can support factor VIII care by identifying patterns in infusion records, bleeding events, laboratory results, and pharmacokinetic data. Potential applications include individualized dose optimization, early detection of adherence challenges, inhibitor-risk signals, inventory planning, and adverse-event surveillance. These tools should remain decision-support systems: their value depends on representative data, transparent validation, clinician oversight, cybersecurity, privacy protection, and clear accountability for treatment decisions.

Regional Insights: Access and Care Models Remain Uneven

North America generally combines specialist hemophilia centers, home-infusion pathways, and established reimbursement mechanisms, while affordability and insurance continuity can still affect access. Europe benefits from coordinated clinical networks and comprehensive registries, though procurement and reimbursement practices vary across countries. Asia-Pacific includes highly developed treatment systems alongside major access gaps, with local manufacturing, training, and diagnostic capacity influencing availability. Latin America continues to strengthen comprehensive care but faces budget, logistics, and geographic barriers. The Middle East shows varied access shaped by national health programs, specialist capacity, and procurement systems. Africa remains constrained in many settings by diagnosis, cold-chain logistics, specialist coverage, and sustained product availability.

Group Insights: Policy Alignment and Procurement Shape Resilience

ASEAN members face differing levels of diagnostic capacity, reimbursement, and specialist coverage, making regional training and coordinated procurement valuable. BRICS countries combine substantial scientific and manufacturing capabilities with wide variation in access, standards, and public-sector delivery. The European Union supports cross-border regulatory and clinical collaboration, while national reimbursement and procurement decisions remain important. G7 systems typically have mature specialist infrastructure but continue to address affordability, supply resilience, and equitable access. GCC countries have opportunities to coordinate procurement and specialist services across well-resourced health systems. NATO members span diverse healthcare structures, so military and civilian preparedness considerations should complement routine hemophilia care without displacing patient-centered services.

Country Insights: National Systems Determine Patient Experience

Australia relies on specialized treatment networks and coordinated public health services across a geographically dispersed population. Brazil combines expert centers with substantial regional variation in diagnosis and continuity of care. Canada’s provincial and territorial structures influence reimbursement, distribution, and access pathways. China is expanding specialist and diagnostic capacity while addressing regional disparities. France, Germany, Italy, and Spain operate established European care systems, with differences in procurement, prescribing, registries, and reimbursement. India faces significant variation between metropolitan and rural services, making diagnosis, affordability, and training priorities. Japan and South Korea have advanced clinical infrastructure with continued attention to aging patients, prophylaxis, and treatment convenience. Mexico is strengthening specialist access while managing geographic and resource differences. Russia’s access is influenced by public procurement, domestic supply considerations, and regional delivery. The United Kingdom combines specialist centers, national guidance, and registry-supported care. The United States has broad specialist and home-treatment infrastructure, alongside complex payer and affordability considerations.

Industry Priorities: Build Reliable, Patient-Centered Factor VIII Care

Leaders should prioritize validated product quality, secure and diversified supply chains, and transparent shortage-contingency plans. Partnerships with hemophilia treatment centers can improve prophylaxis education, inhibitor monitoring, infusion training, and transition support across age groups. Patient-service programs should reduce administrative burden without creating dependence on opaque processes. Organizations should invest in interoperable registries, evidence-based pharmacokinetic tools, and responsible AI governance. Access strategies should be tailored to local reimbursement and logistics realities, with measurable objectives for diagnosis, treatment continuity, safety reporting, and patient-reported outcomes.

Methodology: Evidence-Based Synthesis of Clinical and System Factors

This executive summary uses a structured qualitative synthesis focused on the clinical role and delivery environment of human factor VIII concentrate. The approach considers established hemophilia treatment principles, safety and monitoring requirements, care-delivery models, health-system infrastructure, regulatory and procurement considerations, and documented applications of digital and artificial intelligence tools. Regional, group, and country observations are framed as comparative system-level insights rather than quantitative market claims. Conclusions should be validated against current clinical guidelines, regulatory communications, national policies, registry evidence, and local procurement conditions.

Conclusion: Sustainable Access Depends on Integrated Hemophilia Care

Human factor VIII concentrate remains an important component of hemophilia A management, but its impact depends on more than product availability. Reliable supply, accurate diagnosis, individualized dosing, inhibitor surveillance, specialist support, patient education, and equitable reimbursement must work together. Artificial intelligence can improve coordination and personalization when deployed with strong clinical governance. The most durable progress will come from aligning product quality, health-system resilience, regional collaboration, and patient-centered outcomes.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of extended half-life factor VIII products for improved bleed control in hemophilia A patients
5.2. Increased investment in gene therapy pipelines targeting durable factor VIII expression in hemophilia A
5.3. Shift toward personalized prophylactic dosing strategies using real-time pharmacokinetic monitoring for factor VIII therapy
5.4. Growing demand for plasma-derived factor VIII amid supply chain optimization and donor diversification initiatives
5.5. Emergence of biosimilar factor VIII formulations driving competitive pricing and expanded patient access
5.6. Integration of digital health platforms to track infusion adherence and bleeding episodes in factor VIII treatment
5.7. Innovations in subcutaneous delivery technologies aimed at enhancing patient compliance with factor VIII infusion
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Human Factor VIII Concentrate Market, by Product Type
8.1. Introduction
8.2. Plasma Derived Factor VIII
8.3. Recombinant Factor VIII
8.3.1. Extended Half Life
8.3.1.1. Fc Fusion
8.3.1.2. PEGylated
8.3.1.3. Single Chain
8.3.2. Standard Half Life
8.3.2.1. B Domain Deleted
8.3.2.2. Full Length
9. Human Factor VIII Concentrate Market, by Therapy
9.1. Introduction
9.2. On Demand
9.3. Prophylaxis
10. Human Factor VIII Concentrate Market, by End User
10.1. Introduction
10.2. Hemophilia Treatment Centers
10.3. Home Care Settings
10.4. Hospitals
11. Human Factor VIII Concentrate Market, by Patient Type
11.1. Introduction
11.2. Adult
11.3. Pediatric
12. Human Factor VIII Concentrate Market, by Indication
12.1. Introduction
12.2. Hemophilia A
12.3. Von Willebrand Disease
13. Americas Human Factor VIII Concentrate Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Human Factor VIII Concentrate Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Human Factor VIII Concentrate Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Takeda Pharmaceutical Company Limited
16.3.2. Bayer AG
16.3.3. Pfizer Inc.
16.3.4. Novo Nordisk A/S
16.3.5. CSL Limited
16.3.6. Grifols, S.A.
16.3.7. Octapharma AG
16.3.8. Swedish Orphan Biovitrum AB
16.3.9. Sanofi S.A.
16.3.10. LFB S.A.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. HUMAN FACTOR VIII CONCENTRATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. HUMAN FACTOR VIII CONCENTRATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. HUMAN FACTOR VIII CONCENTRATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. HUMAN FACTOR VIII CONCENTRATE MARKET: RESEARCHAI
FIGURE 26. HUMAN FACTOR VIII CONCENTRATE MARKET: RESEARCHSTATISTICS
FIGURE 27. HUMAN FACTOR VIII CONCENTRATE MARKET: RESEARCHCONTACTS
FIGURE 28. HUMAN FACTOR VIII CONCENTRATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HUMAN FACTOR VIII CONCENTRATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PLASMA DERIVED FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PLASMA DERIVED FACTOR VIII, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY FC FUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY FC FUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PEGYLATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PEGYLATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY SINGLE CHAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY SINGLE CHAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY B DOMAIN DELETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY B DOMAIN DELETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY FULL LENGTH, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY FULL LENGTH, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY ON DEMAND, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY ON DEMAND, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 97. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 98. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 99. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 100. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 101. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 102. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 103. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 104. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 105. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 106. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 107. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 110. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 111. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 113. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 116. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 117. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 118. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 122. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 123. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 195. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 196. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 197. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 198. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 199. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 200. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 204. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 205. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 208. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 209. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 210. GERMANY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 211. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 214. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 215. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 216. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 220. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 221. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. FRANCE HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 244. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 245. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 246. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 247. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 248. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 249. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 250. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 251. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 252. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 253. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 256. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 257. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 258. ITALY HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 259. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 262. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 263. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 264. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 265. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 268. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 269. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. SPAIN HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2018-2024 (USD MILLION)
TABLE 294. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY RECOMBINANT FACTOR VIII, 2025-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2018-2024 (USD MILLION)
TABLE 296. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY EXTENDED HALF LIFE, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY STANDARD HALF LIFE, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY THERAPY, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA HUMAN FACTOR VIII CONCENTRATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. SAUDI

Companies Mentioned

  • Bayer AG
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • LFB S.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026 - Product Image

Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026

  • Clinical Trials
  • 501 Pages
  • Global
From
Advate Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Advate Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Hemophilia Treatment Market - Global Forecast 2026-2032 - Product Image

Hemophilia Treatment Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Recombinant Coagulation Factors - Global Strategic Business Report - Product Image

Recombinant Coagulation Factors - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Hemophilia Market - Forecast from 2026 to 2031 - Product Image

Hemophilia Market - Forecast from 2026 to 2031

  • Report
  • 149 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.